๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Low frequency and low level of elevation of serum CA 72-4 in human carcinomas in comparison with established tumor markers

โœ Scribed by Dr. James T. Wu; Pam Carlisle


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
558 KB
Volume
6
Category
Article
ISSN
0887-8013

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

We evaluated a new circulating tumor marker, CA 72โ€4, by comparing its frequency of appearance and level of elevation with other established tumor markers in serial serum specimens from patients with various carcinomas. We found that CA 72โ€4, though highly expressed and widely found in various tumor tissues, is present at low concentration and frequency in the serum. In breast, colon, ovarian, and pancreatic carcinomas, only 21%, 30.9%, 16%, and 26.5% of specimens, respectively, showed elevated CA 72โ€4. When elevated, the level of elevation was also low, much lower than that of the dominant markers. Poor response of CA 72โ€4 to therapy was especially noticeable in serial specimens. In most cases, the CA 72โ€4 remained normal for the entire series while other markers remained at elevated levels. However, changes of the level of CA 72โ€4 usually paralleled those of other markers but at a much lower concentration. Simultaneous measurement of CA 72โ€4 and CA 19โ€9 appears useful to differentiate colorectal from pancreatic carcinomas when they all contained elevated levels of CA 19โ€9. There was a much higher ratio of CA 72โ€4 to CA 19โ€9 with colon than with pancreatic and other carcinomas (247 ยฑ 524 vs. 4.7 ยฑ 6.8).


๐Ÿ“œ SIMILAR VOLUMES


Low serum albumin levels and liver metas
โœ Dragan Trivanovic; Marija Petkovic; Davor Stimac ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 38 KB

W e read with interest the results from the study of serum albu- min and liver metastasis in patients with carcinomas of unknown primary site by Seve et al. 1 We can present some results from our unpublished study in patients with cancer of unknown primary site in which we explored a set of possible